SpectrumLeaf Europe’s Cannadips CBD pouches and Elevar Hemp CBD oral strips have recently been added to the UK’s Novel Food List.
The published Novel Foods list features CBD products for oral consumption that are considered to be attached to a credible Novel Foods application. These products will be able to remain on the market as they progress towards final authorisation.
With a lengthy process still to go, it is unlikely that any applications will be considered for authorisation before early to mid-2023. Any further authorisations may take another few years.
Read more: EFSA puts CBD Novel Foods evaluations on hold due to lack of data
CEO of SpectrumLeaf Europe, Felix Sundstrom, commented: “We are very excited to have both Cannadips and Elevar Hemp products now part of the official Novel Foods list in the UK, which is one of the leading CBD markets in the world.
“It is crucial to SpectrumLeaf to do our best in keeping our products as transparent as possible in order to help consumers feel comfortable.
“This is especially important since both our Cannadips CBD in-mouth pouches and Elevar Hemp CBD oral strips come in unique formats developed to be absorbed directly through the mucosal membranes in the mouth for optimized efficiency.
“Any additional validations such as being listed on the Novel Foods list will undoubtfully instill further user confidence.
“Although making it onto the list does not mean that our products are fully authorized at this moment, we hope it will help retailers and consumers feel more assured and make informed judgments about purchases.”
At the time of publication of the list, the FSA has stated that although products included on it are classed as “credible”, it does not guarantee they will be authorised for sale.
[activecampaign form=31]
